Deutsche Bank maintains a 'hold' rating on Novo Nordisk with a price target of DKK290 after discussions with the company's head of R&D. Novo Nordisk is cautiously optimistic about its new obesity drug study, cagrisema RD11, which may outperform the previous RD4 trial that disappointed markets. The company is competing fiercely with Eli Lilly in the GLP-1 obesity and diabetes drug market, focusing on next-generation therapies and oral formulations. Despite some positive outlook, Deutsche Bank sees limited upside potential for Novo Nordisk shares currently trading just below the target price.
Novo Nordisk's stock has fallen about 70%, trading at roughly 10 times trailing earnings, presenting a buying opportunity. Despite setbacks in pricing and clinical trials, the company's promising drug pipeline, including high-dose Wegovy and other ca...
Eli Lilly's Mounjaro drug revenue surged 125% to $8.66 billion last quarter, prompting a raised full-year revenue forecast of $82-$85 billion and a market cap near $882 billion. Despite this, shares have already climbed significantly, making further ...
Novo Nordisk initiated a share repurchase program on May 6, 2026, aiming to buy back up to DKK 15 billion worth of B shares over 12 months starting February 4, 2026. As of May 13, 2026, the company has repurchased nearly 16 million B shares at an ave...
Novo Nordisk's oral weight-loss drug Wegovy continues to outperform Eli Lilly's Zepbound in the US market, with about 137,000 prescriptions in its 18th week, despite a 4% weekly decline. Citi notes that actual sales may be higher due to incomplete da...
Novo Nordisk is preparing to launch its Wegovy weight-loss pill outside the U.S. later this year, targeting major international markets like the UK, Germany, and Denmark. The company sees a significant opportunity to expand globally, leveraging teleh...
